VK2735 is a dual agonist of the GLP-1 receptor and GIP receptor, with a similar mechanism of action as tirzepatide, which acts on the same receptors. It is injectable and is being developed by Viking Therapeutics. From Wikipedia
Heavy discontinuation and gastrointestinal side effects raised doubts about its ability to challenge larger rivals in the pill race.
